| Literature DB >> 31695973 |
Nektarios Koufopoulos1, Foteini Antoniadou2, Stefania Kokkali3, Eleni Pigadioti4, Lubna Khaldi2.
Abstract
Invasive lobular carcinoma of the breast is the second most common subtype of breast carcinoma. It accounts for 5-15% of the breast carcinoma cases reported. It shows a different metastatic pattern compared to invasive carcinoma of no special type. There are several variants of this cancer including the classic, solid, signet ring cell, tubulolobular, alveolar, trabecular, pleomorphic, and mixed subtypes each one with a distinctive morphology. Invasive lobular carcinoma has been associated with intracellular mucin production, in the form of intracytoplasmic lumina and signet ring cells whereas extracellular mucin production has been related to carcinomas of ductal origin. A new variant that displays extracellular mucin production was described recently. Only nineteen cases of this rare entity have been reported to date. In this manuscript, we report an additional case of invasive lobular carcinoma with extracellular mucin production, describing its clinico-pathological characteristics, and review the literature on the same.Entities:
Keywords: e-cadherin; extracellular mucin production; invasive lobular breast cancer; mucinous carcinoma of the breast; signet ring
Year: 2019 PMID: 31695973 PMCID: PMC6820319 DOI: 10.7759/cureus.5550
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1The tumor consisted of two distinct components. The first component consisted of ILC of the classical subtype (A) and the second one of a mucinous component consisting of multiple, circumscribed, nodules (B), and patchy extracellular mucin with irregular borders (C). In the mucinous area (D) single tumor cells (red arrows), as well as clusters (yellow arrows) were identified. SRCs were present in both areas (E, F).
ILC: Invasive lobular carcinoma
SRCs: Signet ring cells
Figure 2Immunohistochemical study showed positive staining for ER (A) and negative for PR (B) and HER-2/neu (C). E-Cadherin (D) was negative in tumor cells (yellow arrows) and positive in normal ductal structures (red arrow).
ER: Estrogen receptors
PR: Progesterone receptors
ILC with extracellular mucin production clinicopathological data.
Abbreviations: mm; millimeter, NA; not available P; positive, N; negative, Namp; not amplified, ER; estrogen receptor, PR; progesterone receptor, *; no information, **; isolated tumor cells were found in one lymph node ILC; invasive lobular carcinoma
| Case | Author | Year | Age | Size (mm) | LΝ | Grade | ER % | PR % | HER2 | Ki-67 (%) |
| 1 | Rosa et al. [ | 2009 | 60 | 90 | NA | NA | NA | NA | NA | NA |
| 2 | Yu et al. [ | 2010 | 65 | ΝΑ | 1+ * | NA | 100 | N | 3+ | 25 |
| 3 | Haltas et al. [ | 2012 | 43 | ΝΑ | 1/19 | NA | P | P | N | NA |
| 4 | Bari et al. [ | 2015 | 38 | 35 | 2/10 | NA | P | P | N | NA |
| 5 | Gomez-Macias et al. [ | 2016 | 60 | 9 | 0/4 | 1 | P | 90 | N | NA |
| 6 | Cserni et al. [ | 2017 | 69 | >24 | 1/2 | 2 | 100 | 10 | N | 20 |
| 7 | Cserni et al. [ | 2017 | 65 | 90 | 11/13 | 2 | 90 | 5 | N | 30 |
| 8 | Cserni et al. [ | 2017 | 71 | 46 | 0/3 | 2 | 90 | 40 | 3+ | 10 |
| 9 | Cserni et al. [ | 2017 | 62 | 80 | 10/23 | 2 | 90 | 80 | Namp | 40 |
| 10 | Cserni et al. [ | 2017 | 45 | 29 | 0/2 | 3 | 95 | 95 | N | 40 |
| 11 | Cserni et al. [ | 2017 | 56 | 22 | 0/1 | 2 | 100 | 70 | N | 20 |
| 12 | Cserni et al. [ | 2017 | 75 | 30 | 7/9 | 2/3 | 80 | <1 | N | 20 |
| 13 | Cserni et al. [ | 2017 | 60 | 50 | 3/13 | 2 | 60 | 5 | Namp | 7 |
| 14 | Boukhechba et al. [ | 2018 | 75 | 15 | NA | NA | P | N | N | NA |
| 15 | Singh et al. [ | 2019 | 87 | 100 | 1/3 | 2 | P | NA | N | NA |
| 16 | Singh et al. [ | 2019 | 72 | 16 | NA | 3 | P | NA | N | NA |
| 17 | Singh et al. [ | 2019 | 70 | >20 | 0/10 | 3 | P | NA | N | NA |
| 18 | Singh et al. [ | 2019 | 77 | 8 | 0/2 | 1 | P | NA | N | NA |
| 19 | Baig et al. [ | 2019 | 67 | 60 | 0/2** | 3 | P | N | Namp | NA |
| 20 | Present case | 2019 | 65 | 13 | 0/2 | 2 | 100 | N | N | 10 |
ILC with extracellular mucin production therapeutic approach features.
Abbreviations: M; mastectomy, NA; not available, BCS; breast-conserving surgery, SLNB; sentinel lymph node biopsy, ALND; axillary lymph node dissection, RT; radiotherapy, HT; hormonal therapy, ChT; chemotherapy, Neoadj; neoadjuvant, EB; Excisional biopsy, ILC; invasive lobular carcinoma
| Case | Author | Surgery | Adjuvant therapy | Follow up (months) |
| 1 | Rosa et al. [ | M | NA | NA |
| 2 | Yu et al. [ | BCS + SLNB | NA | NA |
| 3 | Haltas et al. [ | M + ALND | NA | NA |
| 4 | Bari et al. [ | M + ALND | NA | NA |
| 5 | Gomez-Macias et al. [ | BCS + SLNB | RT + HT | NA |
| 6 | Cserni et al. [ | M + SLNB | RT + HT | 26 |
| 7 | Cserni et al. [ | BCS > M | RT + HT + ChT | 40 |
| 8 | Cserni et al. [ | BCS + SNB | RT + HT + ChT | 29 |
| 9 | Cserni et al. [ | BCS > M + ALND | RT | 68 |
| 10 | Cserni et al. [ | BCS + SLNB | RT + ChT | 2 |
| 11 | Cserni et al. [ | M + SLNB | RT | 11 |
| 12 | Cserni et al. [ | EB > M + ALND | Neoadj ChT | 21 |
| 13 | Cserni et al. [ | M + ALND | RT + HT + ChT | NA |
| 14 | Boukhechba et al. [ | NA | NA | NA |
| 15 | Singh et al. [ | NA | NA | NA |
| 16 | Singh et al. [ | NA | NA | NA |
| 17 | Singh et al. [ | NA | NA | NA |
| 18 | Singh et al. [ | NA | NA | NA |
| 19 | Baig et al. [ | BCS | ChT+RT+HT | NA |
| 20 | Present case | M+ SLNB | RT + HT | 8 |